Trial Outcomes & Findings for Treatment of Negative Symptoms of Schizophrenia With Transcranial Magnetic Stimulation (TMS) (NCT NCT00517075)
NCT ID: NCT00517075
Last Updated: 2017-01-13
Results Overview
TERMINATED
PHASE2
14 participants
At baseline, every 2 weeks during rTMS sessions, and at monthly follow-up visits.
2017-01-13
Participant Flow
P.I. has left the institution and NYSPI has no access to the data. Results will not be analyzed or presented.
Participant milestones
| Measure |
High Frequency rTMS
high frequency rTMS to the left infero-parietal lobe, active/sham condition randomized (2:1), double-blind
Transcranial Magnetic Stimulation (TMS): For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
|
Active High Frequency rTMS
Active high frequency rTMS to the left dorsolateral prefrontal cortex
Transcranial Magnetic Stimulation (TMS): For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
|
Sham/Placebo
Sham (placebo) high frequency rTMS to the left dorsolateral prefrontal cortex or left infero-parietal lobe, active/sham condition randomized (2:1), double-blind
Transcranial Magnetic Stimulation (TMS): For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
|
Open Cross Over High Frequency rTMS
Following the randomization phase with three arms, subjects who did not respond, have the possibility of receiving open active treatment to the target that they did not receive treatment to in the randomization phase. (i.e. randomized to IPL --\> open phase DLPFC and vice versa)
repetitive transcranial magnetic stimulation: For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
|
|---|---|---|---|---|
|
Overall Study
STARTED
|
0
|
0
|
0
|
0
|
|
Overall Study
COMPLETED
|
0
|
0
|
0
|
0
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Treatment of Negative Symptoms of Schizophrenia With Transcranial Magnetic Stimulation (TMS)
Baseline characteristics by cohort
Baseline data not reported
PRIMARY outcome
Timeframe: At baseline, every 2 weeks during rTMS sessions, and at monthly follow-up visits.Population: P.I. has left the institution and NYSPI has no access to the data. Results will not be analyzed or presented.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: At baseline, every 2 weeks during rTMS sessions, and at monthly follow-up visits.Population: P.I. has left the institution and NYSPI has no access to the data. Results will not be analyzed or presented.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: At baseline, every 2 weeks during rTMS sessions, and at monthly follow-up visits.Population: P.I. has left the institution and NYSPI has no access to the data. Results will not be analyzed or presented.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: At baseline, every 2 weeks during rTMS sessions, and at monthly follow-up visits.Population: P.I. has left the institution and NYSPI has no access to the data. Results will not be analyzed or presented.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: At baseline and the end of each study phase (random and open)Population: P.I. has left the institution and NYSPI has no access to the data. Results will not be analyzed or presented.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: At baseline, every 2 weeks during rTMS sessions, and at monthly follow-up visits.Population: P.I. has left the institution and NYSPI has no access to the data. Results will not be analyzed or presented.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: At baseline, the first and last rTMS sessions of each study phase (random and open), and at monthly follow-up visits.Population: P.I. has left the institution and NYSPI has no access to the data. Results will not be analyzed or presented.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: At baseline, every 2 weeks during rTMS sessions, and at monthly follow-up visits.Population: P.I. has left the institution and NYSPI has no access to the data. Results will not be analyzed or presented.
Outcome measures
Outcome data not reported
Adverse Events
High Frequency rTMS
Active High Frequency rTMS
Sham/Placebo
Open Cross Over High Frequency rTMS
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place